Genetic test could Fine-Tune transplant drug dosing
NCT ID NCT00552201
Summary
This study tested if adjusting the starting dose of a common anti-rejection drug (tacrolimus) based on a patient's genetics could help get the drug level right more quickly after a kidney transplant. 280 kidney transplant recipients were randomly assigned to receive either a standard starting dose or a dose tailored to their genetic test result. The main goal was to see if more patients in the tailored-dose group reached the target drug level in their blood within the first few days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Angers
Angers, France
-
CHU Gabriel Montpied
Clermont-Ferrand, 63003, France
-
CHU Limoges - Hôpital Dupuytren
Limoges, 87042, France
-
CHU Poitiers- hôpital Jean Bernard
Poitiers, 86021, France
-
CHU Reims - Hôpital Maison Blanche
Reims, 51092, France
-
CHU Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
CHU Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, 76230, France
-
CHU Strasbourg - Hospices Civils
Strasbourg, 67091, France
-
CHU Tours - Hôpital Bretonneau
Tours, 37044, France
-
CHU de la côté de Nacre
Caen, 14033, France
Conditions
Explore the condition pages connected to this study.